BACKGROUND: In addition to enhanced proinflammatory signaling, impaired resolution of vascular inflammation plays a key role in atherosclerosis. Proresolving lipid mediators formed through the 12/15 lipoxygenase pathways exert protective effects against murine atherosclerosis. n-3 Polyunsaturated fatty acids, including eicosapentaenoic acid (EPA), serve as the substrate for the formation of lipid mediators, which transduce potent anti-inflammatory and proresolving actions through their cognate G-protein–coupled receptors. The aim of this study was to identify signaling pathways associated with EPA supplementation and lipid mediator formation that mediate atherosclerotic disease progression.

METHODS: Lipidomic plasma analysis were performed after EPA supplementation in Apoe−/− mice. Erv1/Chemr23−/−xApoe−/− mice were generated for the evaluation of atherosclerosis, phagocytosis, and oxidized low-density lipoprotein uptake. Histological and mRNA analyses were done on human atherosclerotic lesions.

RESULTS: Here, we show that EPA supplementation significantly attenuated atherosclerotic lesion growth induced by Western diet in Apoe−/− mice and was associated with local cardiovascular n-3 enrichment and altered lipoprotein metabolism. Our systematic plasma lipidomic analysis identified the resolvin E1 precursor 18-monohydroxy EPA as a central molecule formed during EPA supplementation. Targeted deletion of the resolvin E1 receptor Erv1/Chemr23 in 2 independent hyperlipidemic murine models was associated with proatherogenic signaling in macrophages, increased oxidized low-density lipoprotein uptake, reduced phagocytosis, and increased atherosclerotic plaque size and necrotic core formation. We also demonstrate that in macrophages the resolvin E1–mediated effects in oxidized low-density lipoprotein uptake and phagocytosis were dependent on Erv1/Chemr23. When analyzing human atherosclerotic specimens, we identified ERV1/ChemR23 expression in a population of macrophages located in the proximity of the necrotic core and demonstrated augmented ERV1/ChemR23 mRNA levels in plaques derived from statin users.

CONCLUSIONS: This study identifies 18-monohydroxy EPA as a major plasma marker after EPA supplementation and demonstrates that the ERV1/ChemR23 receptor for its downstream mediator resolvin E1 transduces protective effects in atherosclerosis. ERV1/ChemR23 signaling may represent a previously unrecognized therapeutic pathway to reduce atherosclerotic cardiovascular disease.
Clinical Perspective

What Is New?
- This study identifies 18-monohydroxy eicosapentaenoic acid as a major plasma lipid metabolite formed during omega-3 supplementation with eicosapentaenoic acid to hyperlipidemic mice.
- 18-Monohydroxy eicosapentaenoic acid is the precursor for the proresolving lipid mediator resolvin E1, which in the present study was shown to regulate critical atherosclerosis-related functions in macrophages through its downstream signaling receptor, ERV1/ChemR23, to transduce protective effects in atherosclerosis.

What Are the Clinical Implications?
- The controversy around the cardioprotective effects of omega-3 polyunsaturated fatty acids urges studies of the mechanisms involved.
- Optimizing treatments for stimulating the resolvin E1 and ERV1/ChemR23 signaling axis may be a potential therapeutic pathway to reduce atherosclerotic cardiovascular disease.

Atherosclerotic lesion development in response to elevated levels of cholesterol-rich lipoproteins is characterized by proinflammatory signaling. Indeed, it was recently demonstrated that blocking proinflammatory signaling without altering lipid levels reduces the risk of recurrent cardiovascular events. Impaired resolution of vascular inflammation plays a key role in atherosclerosis, and proresolving lipid mediators formed through the 12/15 lipoxygenase pathways exert protective effects against murine atherosclerosis.

n-3 Polyunsaturated fatty acids (PUFAs), principally eicosapentaenoic acid (EPA) and docosahexaenoic acid, serve as the substrate for the formation of anti-inflammatory and proresolving lipid mediators with potential beneficial effects in multiple inflammatory diseases, including atherosclerosis. EPA metabolism leads to the formation of 18-monohydroxy EPA (18-HEPE), the precursor for the lipid mediator resolvin E1 (RvE1), which transduces its proresolving actions by means of the G-protein–coupled receptor referred to as ERV1/ChemR23. Indeed, overexpression of ERV1/ChemR23 enhances the effects of RvE1 in different animal models.

In addition, in vivo administration of RvE1 and 15-epi lipoxin A4 to hyperlipidemic mice reduces atherosclerosis progression. Nonetheless, whether and how these lipid mediators and their specific receptors participate in the observed effects of n-3 PUFA supplementation in cardiovascular disease remain largely unexplored.

Deepening the comprehension of the metabolism and signaling associated with n-3 PUFA supplementation is important to understand how to appropriately stimulate specific pathways for therapeutic purposes. In addition, such understanding may also provide explanations for the inconsistent results obtained in clinical trials evaluating the role of n-3 PUFA supplementation in cardiovascular prevention.

The aim of this study was to identify signaling pathways associated with EPA supplementation and lipid mediator formation that mediate atherosclerotic disease progression. When addressing this question, we identified the RvE1 precursor 18-HEPE as a major plasma marker after EPA supplementation, associated with increased tissue concentrations of its bioactive metabolite RvE1. Therefore, we subsequently generated 2 independent Erv1/Chem23–deficient hyperlipidemic murine strains, which exhibited accelerated atherosclerosis. In addition, we demonstrated that in macrophages the RvE1-mediated effects in oxidized (ox) low-density lipoprotein (LDL) uptake and phagocytosis are dependent on Erv1/Chem23. Finally, we provide the translational implications by determining ERV1/ChemR23 expression patterns in human atherosclerosis and their association with statin use.

METHODS

Animal Studies
Animal experiments were conducted in accordance with guidelines from the Directive 2010/63/EU of the European Parliament and were approved by the Ethical Committee of Northern Stockholm. Details about diets (Table I in the online-only Data Supplement), experimental animals (Table II and Figure I in the online-only Data Supplement), materials (Table III in the online-only Data Supplement), and supplemental methods are provided online. The data, analytical methods, and study materials will be made available to other researchers for the purposes of reproducing the results or replicating the procedure (available at the authors’ laboratories).

Human Studies
Informed consent was obtained from all subjects. The investigation was approved by the Ethical Committee of Northern Stockholm and was in agreement with the Declaration of Helsinki.

Statistical Analysis
Experimental results are presented as mean±SEM and clinical parameters as median (interquartile range). All statistical analyses were 2 sided. Adjusted P values are shown for multiple comparisons.

RESULTS

EPA Administration Modifies Fatty Acid Composition in Tissues From Apoe−/− Mice

Apoe−/− mice fed a Western diet supplemented with EPA for 4 weeks exhibited a significant increase in
n-3 PUFAs and a significant reduction in n-6 PUFAs in myocardium, spleen, and skeletal muscle compared with animals fed a Western diet. In those tissues, EPA content was significantly increased by 388-, 384-, and 706–fold, respectively (Table 1).

**EPA Supplementation Attenuates Diet-Induced Atherosclerosis in Apoe⁻/⁻ Mice**

EPA supplementation significantly attenuated atherosclerotic lesion growth induced by Western diet in both the aortic arch (Figure 1A and 1B) and the aortic root (Figure 1C).

No significant differences in blood counts resulting from the different diets were observed. Compared with the animals fed a chow diet, higher body weight was observed in the animals fed a Western diet independently of EPA supplementation (Table II in the online-only Data Supplement).

Nonfasting plasma analyses revealed that the EPA-supplemented animals exhibited a trend toward higher triglyceride levels than the animals fed a Western diet or a chow diet. No significant difference was found between the animals fed a Western and those fed a chow diet. Total plasma cholesterol levels were significantly higher in the animals fed a Western diet than in those fed a chow diet. Despite a trend, total plasma cholesterol levels in the EPA-supplemented animals were not significantly different from those in animals fed a Western or a chow diet (Table 2). Further investigation of the different lipoprotein fractions revealed that compared with Western diet, EPA supplementation significantly decreased very-low-density lipoprotein (VLDL) cholesterol to levels similar to those exhibited by the animals fed a chow diet. LDL and high-density lipoprotein fractions remained similar among the different groups (Figure IIA in the online-only Data Supplement). In addition, EPA supplementation caused a significant decrease of the hepatic mRNA levels of 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (Hmgcr; Figure IIB in the online-only Data Supplement).

**EPA Supplementation Reshapes the Lipid Mediator Profile in Plasma of Apoe⁻/⁻ Mice: Identification of Components of the Erv1/Chemr23 Signaling Pathway**

The experimental diet groups were separated in a principal component analysis model according to their lipid mediator profile (Figure 1D). A heat map analysis showed that EPA supplementation significantly increased the levels of most n-3–derived lipid mediators and reduced those of n-6–derived lipid mediators compared with the animals fed a chow or a Western diet (Figure IC in the online-only Data Supplement). Variable importance for projection scores were calculated from the partial least-squares discriminant analysis (Figure IID).
Figure 1. Eicosapentaenoic acid (EPA) supplementation inhibits diet-induced atherosclerosis and reshapes the lipid mediator profile in plasma of Apoe−/− mice.

A, Apoe−/− mice were fed a chow diet (light gray), a Western diet (WD; 0.15% cholesterol; dark gray), or a WD supplemented with 5% EPA (WD+EPA; medium gray) for 12 weeks. B, Atherosclerotic lesion size determined as percent of Sudan IV staining of the aortic arch (data presented as mean±SEM; 1-way ANOVA followed by Tukey multiple-comparison test; n=8 versus 6 versus 9) and (C) as percent of Oil Red O staining at different levels of the aortic root (data presented as mean±SEM; 2-way ANOVA followed by Tukey multiple-comparison test; n=8 versus 6 versus 9; *WD vs chow, P<0.0001; †WD vs WD+EPA, P<0.0001). D, Two-dimensional principal component analysis of lipid mediators in plasma. Colored spherical areas display 95% confidence region of respective experimental diets. E, Variable importance in projection (VIP) scores of 10 most significant lipid mediators explaining differences in plasma lipid mediator profile between diets. F, Typical example of a chromatogram for chiral assessment of 18-monohydroxy EPA (18-HEPE) in plasma of WD+EPA samples and its comparison with a standard containing equal amounts of 18R-HEPE and 18S-HEPE enantiomers. G, Multiple-reaction monitoring chromatograms depicting the relative quantities of resolvin (Rv) E1 in spleens from mice fed chow, WD, and WD+EPA. Inset shows tandem mass spectrometry spectrum used in the identification of RvE1. H, Splenic concentrations of RvE1 and RvE2 (n=4 mice per group).
in the online-only Data Supplement) and identified 18-HEPE as a critical molecule explaining the differences in plasma lipid mediator profile caused by dietary EPA supplementation (Figure 1E).

Chiral liquid chromatography/tandem mass spectrometry–based lipidomics revealed that the enantiomeric excess was 6.01±1.17% with 53% 18S-HEPE and 47% 18R-HEPE in the plasma of animals receiving EPA supplementation (Figure 1F). These enantiomers serve as the precursors of 18R-RvE1 and 18S-RvE1, 2 short-lived and locally produced lipid mediators with biological actions that are transduced mainly by the receptor ERV1/ChemR23. General lipid profiling methods were unable to detect RvE1 in either plasma or tissue (data not shown). However, analysis of the two 18-HEPE metabolites RvE1 and RvE2 by a targeted lipidomics approach revealed significant increases in RvE1 and RvE2 in spleens derived from EPA-supplemented compared with Western diet–fed mice (Figure 1G and 1H).

Erv1/Chemr23 mRNA expression was identified in the aorta of the animals, being significantly higher in the chow group than in the others (Figure IIE in the online-only Data Supplement).

Chemerin, another precursor for ERV1/ChemR23 ligands, was detected in the plasma of the 3 groups, with significantly higher levels in the Western diet group than in the chow diet group, and was not significantly altered by EPA supplementation (Figure IIF in the online-only Data Supplement).

**Targeted Deletion of Erv1/Chemr23 Enhances Atherosclerosis in Apoe−/− Mice**

After 8 weeks on a Western diet, Apoe−/−xErv1/Chemr23−/− mice exhibited larger atherosclerotic lesions in the aortic arch (Figure 2A and 2B) and the aortic root (Figure 2C) than the control group. No differences in blood counts, weight (Table II in the online-only Data Supplement), plasma triglycerides (1.29±0.2 versus 1.75±0.55 mmol/L; P=0.16), total cholesterol levels (16.70±5.27 versus 22.27±3.4 mmol/L; P=0.13), or lipoprotein profile (Figure 2D) were found between the 2 genotypes. A second group of animals under the same conditions verified these findings (data not shown).

**Targeted Deletion of Erv1/Chemr23 Changes Atherosclerotic Plaque Composition and the Expression of Genes Involved in Lesion Development**

The proportion of lesion area containing CD68+ macrophages was significantly increased in Apoe−/−xErv1/Chemr23−/− mice compared with the control group (Figure 2E). Similar numbers of CD4+ (Figure 2F) and CD8+ (Figure 2G) T cells were identified in the lesions of the 2 genotypes.

Comparative quantitative polymerase chain reaction analyses in abdominal aortas of the 2 genotypes revealed differential expression of genes involved in critical functions associated with atherosclerosis. More specifically, Apoe−/−xErv1/Chemr23−/− mice exhibited significantly increased mRNA levels of genes involved in lipid metabolism and lipoprotein uptake: LDL receptor (Ldlr), VLDL receptor (Vldlr), and sortilin 1 (Sort1); significantly reduced mRNA levels for receptors involved in phagocytosis: macrophage receptor with collagenous structure (Marco) and T-cell immunoglobulin and mucin domain containing 4 (Timd4); and significantly increased mRNA levels of proinflammatory genes: osteoprotegerin (Opg) and Toll-like receptor 4 (Tlr4), accompanied by a reduction in mRNA levels of the anti-inflammatory gene interleukin 10 (Il-10; Figure 2K).

**Apoe−/−xErv1/Chemr23−/− Macrophages Exhibit Increased oxLDL Uptake and Decreased Phagocytosis.**

Apoe−/−xErv1/Chemr23−/− peritoneal macrophages exhibited increased intracellular lipid content after 24 hours of incubation with oxLDL compared with those derived from control mice (Figure 3A). Experiments using fluorescent oxLDL showed that macrophages lacking Erv1/Chemr23 exhibited a significant continued increase in oxLDL uptake for up to 60 hours (Figure 3B and Movie I in the online-only Data Supplement). RvE1 supplementation (Figure 1F). These enantiomers

| Table 2. Nonfasting Plasma Triglycerides and Total Cholesterol Concentrations |
|-----------------------------|-----------------------------|-----------------------------|-----------------------------|-----------------------------|
|                           | Chow (n=8)                  | WD (n=6)                    | WD+EPA (n=9)                | P Value                     |
| Triglycerides              | 1.66±0.05                   | 1.28±0.09                   | 4.60±1.49                   | 0.07                        |
| Total cholesterol          | 7.34±1.14                   | 16.70±2.63*                 | 9.21±2.89                   | 0.031                       |

Values are mean±SEM. EPA indicates eicosapentaenoic acid; and WD, Western diet.

**P**<0.05 versus chow.

**P**<0.05.
Figure 2. Targeted deletion of Erv1/Chemr23 in Apoe−/− mice enhances atherosclerosis and promotes changes in plaque composition and gene expression.
A, Apoe−/−xErv1/Chemr23m/m and Apoe−/−xErv1/Chemr23m/m mice were fed a Western diet 0.15% cholesterol for (B–D) 8 weeks or (E–K) 12 weeks. B and E, Atherosclerotic lesion size determined as percent of Sudan IV staining of the aortic arch (data presented as mean±SEM; Student t test; n=7 versus 6 in B, n=6 in E) and (C and F) as percent of Oil Red O staining at different levels of the aortic root (data presented as mean±SEM; 2-way ANOVA; n=6). D and G, Fast protein liquid chromatographic analysis of plasma lipoprotein profiles. Cholesterol concentration in each fraction (y axis) is expressed as mean±SEM in arbitrary (Continued)
(250 nmol/L) significantly decreased oxLDL uptake in control mice, whereas RvE1 did not significantly alter oxLDL uptake in peritoneal macrophages derived from ApoE<sup>−/−</sup>xErv1/Chemr23<sup>−/−</sup> mice (Figure 3C).

Peritoneal macrophages obtained from ApoE<sup>−/−</sup>xErv1/Chemr23<sup>−/−</sup> mice exhibited reduced phagocytic capacity after 1 hour of incubation with pHrodo-labeled zymosan particles compared with those obtained from control mice (Figure 3D), a difference that persisted over time (Figure 3E). RvE1 (50 nmol/L) significantly increased phagocytosis in wild-type macrophages but did not significantly alter phagocytosis in ApoE<sup>−/−</sup>xErv1/Chemr23<sup>−/−</sup> peritoneal macrophages (Figure 3F).

**ERV1/Chemr23<sup>−/−</sup> Bone Marrow Confers Increased Atherosclerotic Lesions and Necrotic Core in Chimeric Ldlr<sup>−/−</sup> Mice**

Chimeric animals that received Erv1/Chemr23<sup>−/−</sup> bone marrow exhibited larger atherosclerotic lesions in the aortic root than the control group (Figure 4A and 4B). There were no significant differences in blood counts, weight (Table II in the online-only Data Supplement), plasma triglycerides (4.94±2.2 versus 6.39±1.88 mmol/L; P=0.11), total cholesterol (30.14±11.18 versus 35.28±6.35 mmol/L; P=0.2027), and lipoprotein profile (Figure 4C) between the groups. A significant increase in necrotic core size was found in Erv1/Chemr23<sup>−/−</sup> chimeras compared with the control group (Figure 4D).

**ERV1/Chemr23–Expressing Macrophages Localize in the Proximity of the Necrotic Core in Human Atherosclerotic Plaques**

In human atherosclerotic plaques, ERV1/ChemR23 immunoreactivity was observed mainly in the proximity of the necrotic core and less prominently in the fibrous cap (Figure 5A). Smooth muscle actin–positive smooth muscle cells expressed ERV1/ChemR23 in the fibrous cap (Figure 5B) and media regions (Figure 5C); however, the strongest ERV1/ChemR23 expression was associated with the pan-macrophage marker CD68 and specifically located in the proximity of the necrotic core (Figure 5D). Staining with antibodies against ERV1/ChemR23 and CD163, heme oxygenase 1, and arginase 1 revealed that none of these markers were expressed by ERV1/ChemR23<sup>+</sup> cells (Figure 5E–5H).

**ERV1/ChemR23 Expression in Human Atherosclerotic Plaques Is Associated With Key Genes for Lipoprotein Uptake and Phagocytosis**

ERV1/ChemR23 expression exhibited significant, albeit moderate, inverse associations with LDLR, VLDLR, and SORT1 and was significantly positively associated with TIMD4 and MARCO (Figure 5I).

**Statin Users Exhibit Higher ERV1/ChemR23 Expression in Their Atherosclerotic Plaques**

Stratification of the cohort according to the use of statins revealed that ERV1/ChemR23 expression was significantly higher in statin users compared with non-users, whereas age, sex, body mass index, weight, concurrent diabetes mellitus, smoking, plasma levels of triglycerides, high-density lipoprotein, high-sensitivity C-reactive protein, fibrinogen, creatinine, and estimated glomeruli filtration rate were not significantly different between the 2 groups (Table 3). As expected, plasma total cholesterol and LDL cholesterol were significantly reduced in statin users.

**DISCUSSION**

The present study provides a link among EPA supplementation, the generation of the precursors of proreresolving lipid mediators, and their signaling pathways in the context of cardiovascular disease. Specifically, we identify 18-HEPE as a plasma biosynthetic pathway marker of EPA supplementation. We further characterize the receptor for the 18-HEPE–derived lipid mediator RvE1, ERV1/ChemR23, as a key player in atherosclerosis. Targeted deletion of Erv1/Chemr23 in 2 independent hyperlipidemic murine models was associated with proatherogenic signaling in macrophages, increased oxLDL uptake, reduced phagocytosis, and increased atherosclerotic plaque size and necrotic core formation. Moreover, we localized ERV1/ChemR23 expression in human atherosclerotic lesions and demonstrated its augmented expression in statin users. Taken together, these results disclose the RvE1 precursor 18-HEPE as a critical plasma marker formed during EPA supplementation and reveal that RvE1 signaling through ERV1/ChemR23 transduces protective effects in atherosclerosis.
**Figure 3.** Apoe\(^{-/-}\) x Erv1/Chemr23\(^{+/+}\) macrophages exhibit increased oxidized low-density lipoprotein (oxLDL) uptake and decreased phagocytosis. Resolvin E1 (RvE1) effects on oxLDL uptake and phagocytosis are dependent on Erv1/Chemr23.  

**A.** Representative photomicrographs of intracellular lipid content in peritoneal macrophages after 24 hours of incubation with oxLDL using lipophilic fluorophore BODIPY (light gray) and DAPI (dark gray) as nuclei counterstaining.  
**B.** FITC-labeled oxLDL uptake in peritoneal macrophages. Images were collected every 2 hours for a total of 60 hours (data presented as mean±SEM; 2-way ANOVA; n=3).  
**C.** Peritoneal macrophages were stimulated with RvE1 (50–250 nmol/L, 15 minutes) followed by coincubation with FITC-labeled oxLDL (10 µg/mL). Images were collected every 1 hour for a total of 45 hours (data presented as mean±SEM; 2-way ANOVA; n=3).  
**D.** Representative phase-contrast and fluorescence overlay photomicrographs of peritoneal macrophages engulfing pHrodo-labeled zymosan particles (green) after 60 minutes of incubation.  
**E.** Total fluorescence emitted by macrophages engulfing zymosan particles over time (data shown as mean±SEM; 2-way ANOVA; n=5).  
**F.** Peritoneal macrophages were stimulated with RvE1 (50–250 nmol/L, 15 minutes) followed by coincubation with pHrodo-labeled zymosan particles for 2 hours (data shown as mean±SEM; 2-way ANOVA; n=3). AU indicates arbitrary units.
Our study demonstrates that EPA supplementation caused an attenuation of Western diet–induced atherosclerosis. Despite no significant differences in total cholesterol levels, we observed a reduction in VLDL cholesterol and in hepatic Hmgcr expression in the EPA-supplemented animals. Furthermore, EPA was incorporated into cardiovascular structures, where it may serve as a substrate for lipid mediator formation.

Figure 4. Erv1/Chemr23–deficient chimeras display enhanced lesion development and increased necrotic core size. A, Bone marrow (BM) transplantation experimental design: Ldlr<sup>−/−</sup> mice were lethally irradiated and subsequently transplanted with BM from either Erv1/Chemr23<sup>+/+</sup> or Erv1/Chemr23<sup>−/−</sup> mice. After 6 weeks of recovery, the animals were fed a Western diet 1.25% cholesterol for an additional 12-week period. B, Atherosclerotic lesion size determined as percent of Oil Red O staining at different levels of the aortic root (data presented as mean±SEM; 2-way ANOVA; n=7). C, Fast protein liquid chromatographic analysis of plasma lipoprotein profiles. Cholesterol concentration in each fraction (y axis) is expressed as mean±SEM in arbitrary units (AU) and plotted against retention time (x axis). The fractions corresponding to very-low-density lipoprotein (VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL) are indicated (2-way ANOVA; n=5). D, Necrotic core size determined as percent of lesion in Oil Red O stainings of the aortic root. Representative images showing the necrotic core (areas marked with black lines) from the 2 groups of chimeras.
Indeed, n3-derived lipid metabolites were robustly increased in the plasma of EPA-supplemented mice, and 18-HEPE was identified as a critical metabolite formed as a result of this dietary supplementation. Similarly, Endo et al. identified 18-HEPE as a key n-3 metabolite in the context of pressure maladaptive cardiac remodeling using a murine strain capable of producing n-3 PUFA endogenously.

The chiral mediator 18-HEPE is the precursor for the short-lived, locally produced, proresolving, anti-inflammatory RvE1. Here, we identify 18S-HEPE as the predominant enantiomer, a relevant observation because that configuration allows the formation of 18S-RvE1, which, compared with the R configuration, displays increased affinity and potency for the receptor ERV1/ChemR23. It should nonetheless be pointed out that...
Table 3. Stratification of Patients Based On Statin Use

| Variable                        | Statin Use | P Value |
|---------------------------------|------------|---------|
|                                 | No         | Yes     |         |
| Age, y                          | 72 (67.8–79.5) | 72 (65–78) | 0.5014 |
| Sex, n (%)                      | 3.00991    |         |         |
| Male                            | 20 (16)    | 77 (61.6) |         |
| Female                          | 2 (1.6)    | 26 (20.8) |         |
| Body mass index, kg/m²          | 27 (24.3–28.9) | 25.45 (23.7–28.3) | 0.2007 |
| Weight, kg                      | 81 (75–88.5) | 77.85 (70–86) | 0.2557 |
| Smoking, n (%)                  | 0.3039     |         |         |
| No plus former                  | 17 (15.0) | 69 (61.1) |         |
| Yes                             | 3 (2.7)    | 24 (21.2) |         |
| Diabetes mellitus, n (%)        | 0.1566     |         |         |
| No or do not know               | 19 (15.2) | 74 (59.2) |         |
| Yes                             | 3 (2.4)    | 29 (23.2) |         |
| Cholesterol, mmol/L             | 5.5 (3.9–6.1) | 4.2 (3.7–4.9) | 0.0266* |
| Low-density lipoprotein cholesterol, mmol/L | 3.6 (2.1–4.3) | 2.2 (1.9–2.8) | 0.0145* |
| High-density lipoprotein cholesterol, mmol/L | 1.05 (0.9–1.3) | 1.2 (0.9–1.4) | 0.4022 |
| Triglycerides, mmol/L           | 1.55 (1.1–2.5) | 1.5 (1.2–2.1) | 0.6787 |
| Fibrinogen, g/L                 | 3.3 (2.8–4) | 3.6 (3.1–4.5) | 0.3394 |
| High-sensitivity C-reactive protein, mg/L | 4.05 (1.5–9.3) | 2.65 (1.3–6.2) | 0.2882 |
| Creatinine, µmol/L              | 85 (69.8–98.3) | 88 (76–105) | 0.4968 |
| Estimated glomerular filtration rate, mL/min | 81.57 (70.3–98.9) | 75.52 (62.9–88) | 0.1918 |
| Erv1/Chemr23, arbitrary units   | 6.69 (6.4–6.9) | 6.86 (6.7–7.1) | 0.0208* |

Categorical data are reported as count (percentage); numerical data are given as median (interquartile range).

*Significant (P<0.05).

Both configurations are biologically active and enhance macrophage phagocytosis to a similar extent.16 Although RvE1 did not appear in the general lipid profiling,13 a targeted analysis14 of spleen tissue revealed increased RvE1 concentrations after EPA supplementation, which may reflect the inherent nature of RvE1 as a locally produced mediator.

These findings taken together, the observed reduction in atherosclerosis after EPA supplementation could hence reflect the decrease in VLDL or a response to EPA-derived lipid mediators. Indeed, previous studies have shown that RvE1 reduces experimental atherosclerosis.10,17 However, the role of its receptor Erv1/Chemr23 has not previously been explored in this context. After having established Erv1/Chemr23 expression in the aortas of Apoe−/− mice and to avoid the possible confounding effect of EPA in lipoprotein metabolism, we generated Apoe−/−xErv1/Chemr23−/− double-knockout mice to specifically unveil the Erv1/Chemr23 signaling pathway in atherosclerosis.

Erv1/Chemr23−/−deficient mice displayed an accelerated atherosclerosis without alterations in plasma lipids, which was observed at different time points and replicated in a separate series. In an advanced stage of the disease, the difference in lesion size between the 2 genotypes persisted in the aortic arch but not in the root, probably reflecting a plateau phase in lesion growth at this site. Lesion composition analyses revealed an increase in macrophage infiltration, accompanied by significant changes in aortic gene expression in a proinflammatory manner through the upregulation of Opg, and Tlr4 and downregulation of Il-1018–20 in Erv1/Chemr23–deficient mice. Additional significantly increased expression of genes involved in macrophage lipoprotein uptake such as Ldlr, Vidlr, and Sort121–24 and reduction of genes involved in phagocytosis such as Timd4 and Marco25,26 were found in Erv1/Chemr23−/− deficient mice.

On the basis of those findings, we investigated the processes of oxLDL uptake and phagocytosis in peritoneal macrophages and demonstrated that Erv1/Chemr23–deficient macrophages exhibit enhanced oxLDL uptake and decreased phagocytosis, supporting the notion that macrophage Erv1/Chemr23 signaling may transduce protective effects in atherosclerosis. Those observations were further supported by the decreased oxLDL uptake and enhanced macrophage phagocytosis induced by its ligand RvE1 in the present study. These effects of RvE1 were not observed in Erv1/Chemr23−/− macrophages, which underlines the beneficial effects of RvE1 signaling through Erv1/Chemr23 in atherosclerosis. This also lays the foundation for a new function in resolution biology, namely that, in addition to anti-inflammation and enhanced phagocytosis, pro-resolving RvE1 signaling by means of Erv1/Chemr23 may directly decrease oxLDL uptake, which would be expected to limit inflammatory activation and potentially reduce antigen presentation and activation of adaptive immune circuits.1

To further consolidate this notion, we replicated the increased atherosclerosis lesion size by transfer of Erv1/Chemr23−/− bone marrow into Ldlr−/− mice in an advanced stage of the disease. In this model, a remarkable increase in the size of the necrotic core, consistent with our in vitro findings, was also observed. Taken together, these results support the notion that ERV1/ChemR23 plays a critical role in macrophage-specific oxLDL uptake and phagocytosis and that it offers protection against lesion development and necrotic core formation.

It has previously been established that macrophages in human aortic and coronary atherosclerotic lesions express ERV1/ChemR23,27 and this finding was replicated in carotid endarterectomies in the present study. We
show that ERV1/ChemR23 was expressed by a subset of CD68+ macrophages residing in the proximity of the necrotic core. This subpopulation of cells was negative for markers of the M2 and Mox macrophage phenotype, suggesting that ERV1/ChemR23 expression may be specific for a phagocytic macrophage population associated with the necrotic core. The transcriptomic profile of human carotid lesions revealed that ERV1/ChemR23 expression was negatively associated with LDLR, VLDLR, and SORT1 and positively associated with TIMD4 and MARCO, hence supporting the results obtained in the mouse models and encouraging an extrapolation of the beneficial effects of ERV1/ChemR23 signaling to human atherosclerosis. The latter suggestion is further strengthened by our observation that ERV1/ChemR23 mRNA levels were significantly higher in carotid endarterectomies derived from statin users compared with those from patients who did not receive these medications. The observational nature of these human data, however, means that no conclusions of causality can be drawn, and the moderate associations observed should be acknowledged as a limitation. Nevertheless, ERV1/ChemR23 upregulation by statin treatment has been demonstrated in human macrophages, which hence may account for additional enhancement of proresolving pathways in atherosclerosis.

Although the significance of ERV1/ChemR23 signaling has been established in liver and adipose tissue metabolism, the present study is the first to demonstrate the importance of this receptor for atherosclerosis. In contrast, targeting another receptor that transduces lipid mediators and peptide signaling, ALX/FPR2, has generated contradictory results in atherosclerosis, thus illustrating the complexity of the signaling induced by its different ligands. It should be mentioned that, in addition to 18-HEPE–derived RvE1, other ligands for ERV1/ChemR23 exist and may be involved in the generation of the observed phenotype in ERV1/ChemR23–deficient mice. Indeed, we also established differences in chemerin levels resulting from the type of diet, which may further enhance ERV1/ChemR23 signaling in atherosclerosis.

CONCLUSIONS

This study confirms that EPA supplementation attenuates diet-induced atherosclerosis in Apoe−/− mice, associated with local cardiovascular n-3 enrichment and altered lipoprotein metabolism. We extend previous observations by identifying the RvE1 precursor 18-HEPE as a central plasma metabolite formed during EPA supplementation to hyperlipidemic mice. We provide the first evidence for a major role of the RvE1 receptor ERV1/ChemR23 in antiatherogenic macrophage signaling by means of promoting anti-inflammation, decreasing ox-LDL uptake, and enhancing phagocytosis, with implications for atherosclerotic lesion size, plaque macrophage content, and necrotic core formation. Finally, we provide the translational implications of these findings by identifying a specific ERV1/ChemR23–expressing macrophage subtype in the proximity of the necrotic core in human atherosclerotic lesions and its association with lipoprotein uptake and phagocytic markers, as well as an increased ERV1/ChemR23 expression in the plaques of the patients receiving statins. ERV1/ChemR23 signaling pathway may represent a novel potential therapeutic target to reduce atherosclerotic cardiovascular disease.
Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RTP, Libby P, Glynn RJ; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–1131. doi: 10.1056/NEJMoa1707914.

3. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. Nature. 2014;510:92–101. doi: 10.1038/nature13479.

4. Merchel AJ, Ko K, Gotlinger KH, Serhan CN, Chan L. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J. 2008;22:3595–3606. doi: 10.1096/fj.08-112201.

5. Fredman G, Spitze M. Specialized pro-resolving mediators in cardiovascular diseases. Mol Aspects Med. 2017;58:65–71. doi: 10.1016/j.mam.2017.02.003.

6. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase-2 nonsteroidal antiinflammatory drugs and functional processing. J Exp Med. 2000;192:1197–1204.

7. Arita M, Bianchini F, Aliberti J, Shen A, Chiang N, Yang R, Petasis NA, Serhan CN. Stereocchemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med. 2005;201:713–722. doi: 10.1084/jem.20042031.

8. Herrera BS, Hasturk H, Kantarci A, Freire MO, Nguyen O, Kansal S, Van Dyke TE. Impact of resolvin E1 on murine neutrophil phagocytosis in type 2 diabetes. Infect Immun. 2013;81:793–802. doi: 10.1128/IAI.02444-13.

9. Gao L, Faibish D, Fredman G, Herrera BS, Chiang N, Serhan CN, Van Dyke TE. Gypsyro R. Resolvin E1 and chemokine-like receptor 1 mediates bone preservation. J Immunol. 2013;190:689–694. doi: 10.4049/jimmunol.1103688.

10. Hasturk H, Abdallah R, Kantarci A, Nguyen D, Giordano N, Hamilton J, Van Dyke TE. Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. Arterioscler Thromb Vasc Biol. 2015;35:1123–1133. doi: 10.1161/ATVBAHA.115.305242.

11. Petri MH, Laguna-Fernández A, Arnardottir H, Wheelock CE, Perretti M, Hansson GK, Bäck M. Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E-/- mice. Br J Pharmacol. 2017;174:4043–4054. doi: 10.1111/bph.13707.

12. Sivkovics DS, Barringer TA, Fretts AM, Wu JH, Lichtenstein AH, Costello RB, Kris-Etherton PM, Jacobson TA, Engler MB, Alger HM, Appel LJ, Mozaffarian D. American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health, Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing, and Council on Clinical Cardiology. Omega-3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association. Circulation. 2017;135:e67–e884. doi: 10.1161/CIR.0000000000000492.

13. Balgoma D, Yang M, Spöck M, Snowden S, Karimi R, Levänen B, Merikallio H, Kaarteenaho R, Palmberg L, Larsson K, Erle DJ, Dahlén SE, Dahlén B, Fujihara H, Koizumi S, Kasagawa T, Irie J, Kruth H, Rader DJ. Macrophage sortilin promotes LDL uptake, foam cell formation, and atherosclerosis. J. Clin. Invest. 2017;137:e867–e884. doi: 10.1172/JCI89715.

14. Oh SF, Pillai PS, Recchiuti A, Yang R, Serhan CN. Pro-resolving lipid mediators attenuate atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin. Atherosclerosis. 2016;250:158–165. doi: 10.1016/j.atherosclerosis.2016.05.001.

15. Perez de Ciriza C, Lawrie A, Varo M, Osteoprotegerin in cardiometabolic disorders. Int J Endocrinol. 2015;2015:564934.